Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director
GlobeNewswire - Mon Apr 14, 3:57PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the appointment of Mary Lynne Hedley, Ph.D. as a director of Receptos. Dr. Hedley will serve as a Class I director with a term of office expiring and to be renewed at the 2014 annual meeting of stockholders. Dr. Hedley will also serve as a member of the Board's Nominating and Corporate Governance Committee.
Healthcare Companies Report Regulatory Affirmations, MPA Inspections, Enrollment in Trials, Stock Movements - Analyst Notes on Halozyme, Align Technology, Cambrex, Receptos, and Anacor Pharmaceuticals
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Halozyme Therapeutics, Inc. (NASDAQ: HALO), Align Technology Inc. (NASDAQ: ALGN), Cambrex Corporation. (NYSE: CBM), Receptos, Inc. (NASDAQ: RCPT), and Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 04, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Is Teva Pharmaceutical Industries Ltd Turning a Corner?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Mar 27, 5:30PM CDT
Once a darling of the health care space (and a frequent member of "buy and hold forever" lists), Teva Pharmaceuticals spent about three and a half years in the market's doghouse. Investors bailed out due to worries about competition in the...
3 Biotechs Falling Like a Knife: Arrowhead, Celldex, Receptos
George Budwell, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
By all accounts, biotech has had a rough week. The iShares Nasdaq Biotechnology Index is down more than 8%, and concerns over a bubble abound. Yet some companies are falling much faster than the broader sector. Are these companies becoming value...
Receptos to Present at BioCentury Future Leaders Conference
GlobeNewswire - Thu Mar 20, 7:14AM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that its President and Chief Executive Officer, Faheem Hasnain, will be presenting at the BioCentury Future Leaders in the Biotech Industry Conference at the Millennium Hotel in New York City. The presentation is scheduled for Friday, March 28, 2014, at 10:00 am Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
BioMed Realty Trust Leases Space To Life Science Firms
at Investor's Business Daily - Wed Mar 19, 4:05PM CDT
Strength in biotech stocks has been well -documented in recent months. Innovation abounds in the sector, and new companies are sprouting up all the time. BioMed Realty Trust (BMR) is a real-estate investment trust poised to benefit from continued...
Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Why Receptos Inc. Shares Briefly Popped
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 3:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Receptos , a clinical-stage...
Receptos Reports Fourth Quarter and Year End 2013 Operational and Financial Results
GlobeNewswire - Wed Mar 05, 3:06PM CST
- Favorable interim results from Phase 2 trial of RPC1063 in relapsing multiple sclerosis consistent with differentiated profile; top-line data expected mid-2014 -
Receptos to Hold Fourth Quarter and Year End 2013 Financial Results Conference Call and Webcast
GlobeNewswire - Thu Feb 27, 8:52AM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the fourth quarter and year ended December 31, 2013 on Wednesday, March 5, 2013 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time).
Sheila Gujrathi, M.D., Joins Ambrx Board of Directors
PR Newswire - Mon Feb 24, 8:00AM CST
Ambrx Inc. today announced that Sheila Gujrathi, M.D., has joined its board of directors. Dr. Gujrathi is currently the chief medical officer at Receptos (Nasdaq: RCPT) where she is responsible for the clinical development of therapeutic candidates for the treatment of immune and metabolic diseases.
5 Biotech Stocks Spiking on Unusual Volume
at The Street - Mon Feb 10, 7:42AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Will Receptos (RCPT) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 6:25AM CST
Will Receptos (RCPT) Continue to Surge Higher?
Analyst Reason No. 345 to Upgrade Biotech Stocks: Takeover Rumors in the Foreign Press!
at The Street - Fri Jan 24, 2:40PM CST
In the past two months, BMO Capital Markets biotech analyst Jim Birchenough has upgrade stocks based on takeover rumors published in overseas newspapers.
Receptos Announces Closing of Underwritten Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Jan 14, 8:46AM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today closing of the previously announced underwritten public offering of 3,320,000 shares of its common stock at a price to the public of $30.75 per share, as well as the full exercise of the option granted to the underwriters to purchase an aggregate of 498,000 additional shares of common stock. The gross proceeds to Receptos from this offering were approximately $117.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering were sold by Receptos.
Stock Price Movements, FDA Applications, Appointments, and Clinical Study Updates - Research Report on Alere, ARCA, Achillion, Idenix Pharmaceuticals, and Receptos
PR Newswire - Mon Jan 13, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Alere Inc. (NYSE: ALR), ARCA biopharma, Inc. (NASDAQ: ABIO), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and Receptos, Inc. (NASDAQ: RCPT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Receptos (RCPT) in Focus: Stock Moves 12.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 10, 8:46AM CST
Receptos was a big mover last session, with shares rising nearly 13%.
Nasdaq stocks posting largest volume increases
AP - Thu Jan 09, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading: